細胞治療および遺伝子治療のサプライチェーンソフトウェア市場- プロセスコンポーネント別、ソフトウェアタイプ別、展開形態別、事業規模別、エンドユーザータイプ別、主要地域別：業界動向と世界の予測

細胞治療および遺伝子治療のサプライチェーンソフトウェアの市場規模は、2024年に2,740億米ドルになるとみられ、予測期間の2024年～2035年のCAGRは15.2％になると予測されています。

先駆的な細胞治療および遺伝子治療はヘルスケアのパラダイムシフトを起こし、最先端医療の開発・生産・消費に革命をもたらしました。これらの画期的な治療薬は、かつては克服不可能と思われた希少な臨床症状と闘うために、ヘルスケア専門家に力を与えてきました。過去数十年にわたり、このような変革的な治療法は30以上の規制当局の承認を得ており、最近の成功例としては、ELEVIDYS（R）（2023年）、Adstiladrin（R）（2022年）、Breyanzi（R）（2022年）、CARVYKTI（R）（2022年）、Abecma（R）（2021年）、Allocord（TM）（2019年）、LUXTURNA（TM）（2017年）、Yescarta（R）（2017年）が挙げられます。注目すべきは、2018年以降、希少疾患に対応する臨床試験の40％以上が革新的な細胞治療および遺伝子治療製品の評価に関与していることです。現在のパイプラインと過去の臨床成功率に基づく予測では、米国食品医薬品局は2025年まで毎年10～20の先進療法を承認する可能性があります。その結果、サプライチェーン管理を合理化する革新的なソフトウェア・ソリューションの需要が急増し、細胞治療および遺伝子治療ソフトウェアプロバイダーに成長機会がもたらされます。

重要なことは、細胞治療および遺伝子治療製品の商業的勝利は、その治療効果だけでなく、複雑なサプライチェーンの複雑さをシームレスにナビゲートする開発者の能力にかかっているということです。細胞治療および遺伝子治療製品のサプライチェーンは、その温度感受性と独自性から、従来の医薬品サプライチェーンよりも本質的に複雑です。その結果、治療法の開発者は、オペレーションの非効率性、キャパシティ・スケジューリングの課題、資本損失につながるプロセスの遅延、配送・追跡に関連する問題など、さまざまなリスクに対処しなければなりません。市場では、こうしたソフトウェアソリューションの発展を目指したパートナーシップが急増しています。さらに、費用対効果の高い個別化医薬品に対する需要の高まりと、こうしたソフトウェアソリューションの導入によるコスト削減の可能性によって、細胞治療および遺伝子治療のサプライチェーンソフトウェア市場は大幅な成長を遂げようとしています。

当レポートでは、世界の細胞治療および遺伝子治療のサプライチェーンソフトウェア市場について調査し、市場の概要とともに、プロセスコンポーネント別、ソフトウェアタイプ別、展開形態別、事業規模別、エンドユーザータイプ別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 序文

第2章 調査手法

第3章 経済およびその他のプロジェクト特有の考慮事項

第4章 エグゼクティブサマリー

第5章 イントロダクション

• 章の概要
• 細胞治療の概要
• 先進治療医薬品（ATMP）
• 細胞治療および遺伝子治療サプライチェーンの概要
• 最近の動向と今後の見通し

第6章 市場情勢

第7章 企業競合分析

• 章の概要
• 前提と主要なパラメータ
• 調査手法
• 企業競合分析：細胞治療および遺伝子治療のサプライチェーンソフトウェアプロバイダー

第8章 企業プロファイル

第9章 資金調達と投資分析

• 章の概要
• 資金調達モデル
• 細胞治療および遺伝子治療のサプライチェーンソフトウェア：資金調達と投資分析
• 結論

第10章 パートナーシップとコラボレーション

第11章 サプライチェーンソフトウェアソリューション市場におけるプラットフォーム利用契約

第12章 ステークホルダーのニーズ分析

第13章 市場への影響分析：促進要因、抑制要因、機会、課題

• 章の概要
• 市場の促進要因
• 市場の抑制要因
• 市場の機会
• 市場の課題
• 結論

第14章 世界の細胞治療および遺伝子治療のサプライチェーンソフトウェア市場

第15章 細胞治療および遺伝子治療のサプライチェーンソフトウェア市場：プロセスコンポーネント別

第16章 細胞治療および遺伝子治療のサプライチェーンソフトウェア市場：ソフトウェアタイプ別

第17章 細胞治療および遺伝子治療のサプライチェーンソフトウェア市場：展開モード別

第18章 細胞治療および遺伝子治療のサプライチェーンソフトウェア市場：事業規模別

第19章 細胞治療および遺伝子治療のサプライチェーンソフトウェア市場：エンドユーザータイプ別

第20章 細胞治療および遺伝子治療のサプライチェーンソフトウェア市場：主要地域別

第21章 結論

第22章 エグゼクティブインサイト

第23章 付録1：表形式のデータ

第24章 付録2：企業・団体一覧

List of Tables

• Table 5.1 Therapeutic Applications of Cell Therapies
• Table 6.1 Cell and Gene Therapy Supply Chain Software: Information on Type of Software and Key Features Offered
• Table 6.3 Cell and Gene Therapy Supply Chain Software: Information on Application Area
• Table 6.4 Cell and Gene Therapy Supply Chain Software: Information on Mode of Deployment and Scale of Operation
• Table 6.5 Cell and Gene Therapy Supply Chain Software: Information on Regulatory Guidelines Followed
• Table 6.6 Cell and Gene Therapy Supply Chain Software: Information on Type of End-User
• Table 6.7 List of Cell and Gene Therapy Supply Chain Software Developers
• Table 8.1 Cell and Gene Therapy Supply Chain Software: List of Companies Profiled
• Table 8.2 Cell and Gene Therapy Supply Chain Software: List of Other Leading Players
• Table 8.3 Azenta Life Sciences: Company Overview
• Table 8.4 Azenta Life Sciences: Supply Chain Management Solutions Portfolio
• Table 8.5 Azenta Life Sciences: Recent Developments and Future Outlook
• Table 8.6 NMDP BioTherapies: Company Overview
• Table 8.7 NMDP BioTherapies: Supply Chain Management Solutions Portfolio
• Table 8.8 NMDP BioTherapies: Recent Developments and Future Outlook
• Table 8.9 Biocair: Company Overview
• Table 8.10 Biocair: Supply Chain Management Solutions Portfolio
• Table 8.11 Biocair: Recent Developments and Future Outlook
• Table 8.12 BioLife Solutions: Company Overview
• Table 8.13 BioLife Solutions: Supply Chain Management Solutions Portfolio
• Table 8.14 BioLife Solutions: Recent Developments and Future Outlook
• Table 8.15 CareDx: Company Overview
• Table 8.16 CareDx: Supply Chain Management Solutions Portfolio
• Table 8.17 CareDX: Recent Developments and Future Outlook
• Table 8.18 Cryoport: Company Overview
• Table 8.19 Cryoport: Supply Chain Management Solutions Portfolio
• Table 8.20 Cryoport: Recent Developments and Future Outlook
• Table 8.21 Lonza: Company Overview
• Table 8.22 Lonza: Supply Chain Management Solutions Portfolio
• Table 8.23 Lonza: Recent Developments and Future Outlook
• Table 8.24 TraceLink: Company Overview
• Table 8.25 TraceLink: Supply Chain Management Solutions Portfolio
• Table 8.26 TraceLink: Recent Developments and Future Outlook
• Table 8.27 TrakCel: Company Overview
• Table 8.28 TrakCel: Supply Chain Management Solutions Portfolio
• Table 8.29 TrakCel: Recent Developments and Future Outlook
• Table 8.30 Veeva Systems: Company Overview
• Table 8.31 Veeva Systems: Supply Chain Management Solutions Portfolio
• Table 8.32 Veeva Systems: Recent Developments and Future Outlook
• Table 8.33 Emerson: Company Overview
• Table 8.34 Emerson: Supply Chain Management Solutions Portfolio
• Table 8.35 LabVantage Solutions: Company Overview
• Table 8.36 LabVantage Solutions: Supply Chain Management Solutions Portfolio
• Table 8.37 Marken: Company Overview
• Table 8.38 Marken: Supply Chain Management Solutions Portfolio
• Table 8.39 MasterControl: Company Overview
• Table 8.40 MasterControl: Supply Chain Management Solutions Portfolio
• Table 8.41 QuickSTAT: Company Overview
• Table 8.42 QuickSTAT: Supply Chain Management Solutions Portfolio
• Table 8.43 Siemens: Company Overview
• Table 8.44 Siemens: Supply Chain Management Solutions Portfolio
• Table 8.45 Stafa Cellular Therapy: Company Overview
• Table 8.46 Stafa Cellular Therapy: Supply Chain Management Solutions Portfolio
• Table 8.47 Steiner: Company Overview
• Table 8.48 Steiner: Supply Chain Management Solutions Portfolio
• Table 8.49 STEMSOFT Software: Company Overview
• Table 8.50 STEMSOFT Software: Supply Chain Management Solutions Portfolio
• Table 8.51 TECHNIDATA: Company Overview
• Table 8.52 TECHNIDATA: Supply Chain Management Solutions Portfolio
• Table 8.53 Thermo Fisher Scientific: Company Overview
• Table 8.54 Thermo Fisher Scientific: Supply Chain Management Solutions Portfolio
• Table 9.1 Cell and Gene Therapy Supply Chain Software: List of Funding and Investments, 2014-2023
• Table 10.1 Cell and Gene Therapy Supply Chain Software: List of Partnerships and Collaborations, 2019-2024
• Table 11.1 Cell and Gene Therapy Supply Chain Software: List of Platform Utilization Agreements, 2019-2024
• Table 22.1 TrakCel: Company Snapshot
• Table 22.2 Cell and Gene Therapy Catapult: Company Snapshot
• Table 22.3 McKesson: Company Snapshot
• Table 22.4 Inlog: Company Snapshot
• Table 22.5 Thermo Fisher Scientific: Company Snapshot
• Table 23.1 Cell and Gene Therapy Supply Chain Software: Distribution by Type of Software
• Table 23.2 Cell and Gene Therapy Supply Chain Software: Distribution by Key Features
• Table 23.3 Cell and Gene Therapy Supply Chain Software: Distribution by Application Area
• Table 23.4 Cell and Gene Therapy Supply Chain Software: Distribution by Mode of Deployment
• Table 23.5 Cell and Gene Therapy Supply Chain Software: Distribution by Type of Software and Mode of Deployment
• Table 23.6 Cell and Gene Therapy Supply Chain Software: Distribution by Scale of Operation
• Table 23.7 Cell and Gene Therapy Supply Chain Software: Distribution by Type of Software and Scale of Operation
• Table 23.8 Cell and Gene Therapy Supply Chain Software: Distribution by Regulatory Guidelines Followed
• Table 23.9 Cell and Advanced Therapies Supply Chain Management Software: Distribution by Type of End-User
• Table 23.10 Cell and Gene Therapy Supply Chain Software: Distribution by Type of Software and Type of End-User
• Table 23.11 Cell and Gene Therapy Supply Chain Software Developers: Distribution by Year of Establishment
• Table 23.12 Cell and Gene Therapy Supply Chain Software Developers: Distribution by Company Size
• Table 23.13 Cell and Gene Therapy Supply Chain Software Developers: Distribution by Year of Establishment and Company Size
• Table 23.14 Cell and Gene Therapy Supply Chain Software Developers: Distribution by Location of Headquarters (Region)
• Table 23.15 Cell and Gene Therapy Supply Chain Software Developers: Distribution by Location of Headquarters (Country)
• Table 23.16 Cell and Gene Therapy Supply Chain Software Developers: Distribution by Number of Software Solutions Offered
• Table 23.17 Most Active Players: Distribution by Number of Software Solutions Offered
• Table 23.18 Azenta Life Sciences: Annual Revenues, FY 2020-FY 2023 (USD Million)
• Table 23.19 NMDP BioTherapies: Annual Revenues, FY 2019 - FY 2022 (USD Million)
• Table 23.20 BioLife Solutions: Annual Revenues, FY 2020 - FY 2023 (USD Million)
• Table 23.21 CareDx: Annual Revenues, FY 2018 - FY 2021 (USD Million)
• Table 23.22 Cryoport: Annual Revenues, FY 2019 - 9M FY 2023 (USD Million)
• Table 23.23 Lonza: Annual Revenues, FY 2019 - FY 2023 (CHF Million)
• Table 23.24 Veeva Systems: Annual Revenues, FY 2020 - FY 2023 (USD Million)
• Table 23.25 Funding and Investment Analysis: Cumulative Year-wise Trend, 2014-2023
• Table 23.26 Funding and Investment Analysis: Distribution by Amount Invested, 2014-2023 (USD Million)
• Table 23.27 Funding and Investment Analysis: Distribution by Type of Funding, 2014-2023
• Table 23.28 Funding and Investment Analysis: Distribution by Type of Funding and Amount Invested (USD Million)
• Table 23.29 Funding and Investment Analysis: Distribution of Amount Invested by Year and Type of Funding, 2014-2023
• Table 23.30 Funding and Investment Analysis: Geographical Distribution of Funding Instances and Amount Invested
• Table 23.31 Funding and Investment Analysis: Geographical Distribution of Funding Instances (Country)
• Table 23.32 Most Active Players: Distribution by Number of Funding Instances
• Table 23.33 Most Active Players: Distribution by Amount Raised (USD Million)
• Table 23.34 Key Investors: Distribution by Number of Funding Instances
• Table 23.35 Funding and Investment Analysis: Distribution by Type of Investor
• Table 23.36 Partnerships and Collaborations: Cumulative Year-wise Trend of Partnerships, 2019-2024
• Table 23.37 Partnerships and Collaborations: Distribution by Type of Partnership
• Table 23.38 Partnerships and Collaborations: Distribution by Year and Type of Partnership
• Table 23.39 Partnerships and Collaborations: Distribution by Type of Partnership and Company Size
• Table 23.40 Partnerships and Collaborations: Distribution by Type of Software Involved
• Table 23.41 Partnerships and Collaborations: Distribution by Type of Partner
• Table 23.42 Most Active Players: Distribution by Number of Partnerships
• Table 23.43 Partnerships and Collaborations: Local and International Agreements
• Table 23.44 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
• Table 23.45 Platform Utilization Agreements: Cumulative Year-wise Trend of Agreements, 2019-2024
• Table 23.46 Platform Utilization Agreements: Distribution by Type of Partner
• Table 23.47 Platform Utilization Agreements: Distribution by Type of Software Involved
• Table 23.48 Platform Utilization Agreements: Distribution by Type of Partner and Type of Software Involved
• Table 23.49 Platform Utilization Agreements: Distribution of Partners by Geography
• Table 23.50 Most active Players: Distribution by Number of Platform Utilization Agreements
• Table 23.51 Global Cell and Gene Therapy Supply Chain Software Market, Historical Trends (2018-2023) (USD Million)
• Table 23.52 Global Cell and Gene Therapy Supply Chain Software Market, Forecasted Estimates (2024-2035) Conservative, Base and Optimistic Scenarios (USD Million)
• Table 23.53 Cell and Gene Therapy Supply Chain Software Market: Distribution by Process Component, 2018, 2024 and 2035 (USD Million)
• Table 23.54 Cell and Gene Therapy Supply Chain Software Market for Sample Collection and Processing Component: Historical Trends (2018-2023) (USD Million)
• Table 23.55 Cell and Gene Therapy Supply Chain Software Market for Sample Collection and Processing Component: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
• Table 23.56 Cell and Gene Therapy Supply Chain Software Market for Manufacturing Component: Historical Trends (2018-2023) (USD Million)
• Table 23.57 Cell and Gene Therapy Supply Chain Software Market for Manufacturing Component: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
• Table 23.58 Cell and Gene Therapy Supply Chain Software Market for Logistics Component: Historical Trends (2018-2023) (USD Million)
• Table 23.59 Cell and Gene Therapy Supply Chain Software Market for Logistics Component: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
• Table 23.60 Cell and Gene Therapy Supply Chain Software Market for Patient Identification and Treatment Follow-Up Component: Historical Trends (2018-2023) (USD Million)
• Table 23.61 Cell and Gene Therapy Supply Chain Software Market for Patient Identification and Treatment Follow-Up Component: Forecasted Estimates (2024-2035), Conservative,Base and Optimistic Scenarios (USD Million)
• Table 23.62 Cell and Gene Therapy Supply Chain Software Market: Distribution by Type of Software, 2018, 2024 and 2035 (USD Million)
• Table 23.63 Cell and Gene Therapy Supply Chain Software Market for EMS: Historical Trends (2018-2023) (USD Million)
• Table 23.64 Cell and Gene Therapy Supply Chain Software Market for EMS: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
• Table 23.65 Cell and Gene Therapy Supply Chain Software Market for LIMS: Historical Trends (2018-2023) (USD Million)
• Table 23.66 Cell and Gene Therapy Supply Chain Software Market for LIMS: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
• Table 23.67 Cell and Gene Therapy Supply Chain Software Market for IMS: Historical Trends (2018-2023) (USD Million)
• Table 23.68 Cell and Gene Therapy Supply Chain Software Market for IMS: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
• Table 23.69 Cell and Gene Therapy Supply Chain Software Market for COP: Historical Trends (2018-2023) (USD Million)
• Table 23.70 Cell and Gene Therapy Supply Chain Software Market for COP: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
• Table 23.71 Cell and Gene Therapy Supply Chain Software Market for QMS: Historical Trends (2018-2023) (USD Million)
• Table 23.72 Cell and Gene Therapy Supply Chain Software Market for QMS: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
• Table 23.73 Cell and Gene Therapy Supply Chain Software Market for LMS: Historical Trends (2018-2023) (USD Million)
• Table 23.74 Cell and Gene Therapy Supply Chain Software Market for LMS: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
• Table 23.75 Cell and Gene Therapy Supply Chain Software Market for PMS: Historical Trends (2018-2023) (USD Million)
• Table 23.76 Cell and Gene Therapy Supply Chain Software Market for PMS: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
• Table 23.77 Cell and Gene Therapy Supply Chain Software Market: Distribution by Mode of Deployment, 2018, 2024 and 2035 (USD Million)
• Table 23.78 Cell and Gene Therapy Supply Chain Software Market for On-premise Deployment: Historical Trends (2018-2023) (USD Million)
• Table 23.79 Cell and Gene Therapy Supply Chain Software Market for On-premise Deployment: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USDMillion)
• Table 23.80 Cell and Gene Therapy Supply Chain Software Market for Cloud-based Deployment: Historical Trends (2018-2023) (USD Million)
• Table 23.81 Cell and Gene Therapy Supply Chain Software Market for Cloud-based Deployment: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
• Table 23.82 Cell and Gene Therapy Supply Chain Software Market: Distribution by Scale of Operation, 2018, 2024 and 2035 (USD Million)
• Table 23.83 Cell and Gene Therapy Supply Chain Software Market for Clinical Scale: Historical Trends (2018-2023) (USD Million)
• Table 23.84 Cell and Gene Therapy Supply Chain Software Market for Clinical Scale: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
• Table 23.85 Cell and Gene Therapy Supply Chain Management Software Market for Commercial Scale: Historical Trends (2018-2023) (USD Million)
• Table 23.86 Cell and Gene Therapy Supply Chain Management Software Market for Commercial Scale: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
• Table 23.87 Cell and Gene Therapy Supply Chain Software Market: Distribution by Type of End-User, 2018, 2024 and 2035 (USD Million)
• Table 23.88 Cell and Gene Therapy Supply Chain Software Market for Pharmaceutical Companies: Historical Trends (2018-2023) (USD Million)
• Table 23.89 Cell and Gene Therapy Supply Chain Software Market for Pharmaceutical Companies: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
• Table 23.90 Cell and Gene Therapy Supply Chain Software Market for Cell Therapy Labs: Historical Trends (2018-2023) (USD Million)
• Table 23.91 Cell and Gene Therapy Supply Chain Software Market for Cell Therapy Labs: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
• Table 23.92 Cell and Gene Therapy Supply Chain Software Market for Hospitals / Medical Centers: Historical Trends (2018-2023) (USD Million)
• Table 23.93 Cell and Gene Therapy Supply Chain Software Market for Hospitals / Medical Centers: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
• Table 23.94 Cell and Gene Therapy Supply Chain Software Market for Research Institutes / Biobanks: Historical Trends (2018-2023) (USD Million)
• Table 23.95 Cell and Gene Therapy Supply Chain Software Market for Research Institutes / Biobanks: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
• Table 23.96 Cell and Gene Therapy Supply Chain Software Market: Distribution by Key Geographical Regions, 2018, 2024 and 2035 (USD Million)
• Table 23.97 Cell and Gene Therapy Supply Chain Software Market in North America: Historical Trends (2018-2023) (USD Million)
• Table 23.98 Cell and Gene Therapy Supply Chain Software Market in North America: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
• Table 23.99 Cell and Gene Therapy Supply Chain Software Market in the US: Historical Trends (2018-2023) (USD Million)
• Table 23.100 Cell and Gene Therapy Supply Chain Software Market in the US: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
• Table 23.101 Cell and Gene Therapy Supply Chain Software Market in Canada: Historical Trends (2018-2023) (USD Million)
• Table 23.102 Cell and Gene Therapy Supply Chain Software Market in Canada: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
• Table 23.103 Cell and Gene Therapy Supply Chain Software Market in Europe: Historical Trends (2018-2023) (USD Million)
• Table 23.104 Cell and Gene Therapy Supply Chain Software Market in Europe: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
• Table 23.105 Cell and Gene Therapy Supply Chain Management Software Market in the UK: Historical Trends (2018-2023) (USD Million)
• Table 23.106 Cell and Gene Therapy Supply Chain Management Software Market in the UK: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
• Table 23.107 Cell and Gene Therapy Supply Chain Management Software Market in Germany: Historical Trends (2018-2023) (USD Million)
• Table 23.108 Cell and Gene Therapy Supply Chain Management Software Market in Germany: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
• Table 23.109 Cell and Gene Therapy Supply Chain Software Market in France: Historical Trends (2018-2023) (USD Million)
• Table 23.110 Cell and Gene Therapy Supply Chain Software Market in France: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
• Table 23.111 Cell and Gene Therapy Supply Chain Software Market in Italy: Historical Trends (2018-2023) (USD Million)
• Table 23.112 Cell and Gene Therapy Supply Chain Software Market in Italy: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
• Table 23.113 Cell and Gene Therapy Supply Chain Software Market in Switzerland: Historical Trends (2018-2023) (USD Million)
• Table 23.114 Cell and Gene Therapy Supply Chain Software Market in Switzerland: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
• Table 23.115 Cell and Gene Therapy Supply Chain Software Market in Rest of Europe: Historical Trends (2018-2023) (USD Million)
• Table 23.116 Cell and Gene Therapy Supply Chain Software Market in Rest of Europe: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
• Table 23.117 Cell and Gene Therapy Supply Chain Software Market in Asia-Pacific: Historical Trends (2018-2023) (USD Million)
• Table 23.118 Cell and Gene Therapy Supply Chain Software Market in Asia-Pacific: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
• Table 23.119 Cell and Gene Therapy Supply Chain Software Market in Australia: Historical Trends (2018-2023) (USD Million)
• Table 23.120 Cell and Gene Therapy Supply Chain Software Market in Australia: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
• Table 23.121 Cell and Gene Therapy Supply Chain Software Market in China: Historical Trends (2018-2023) (USD Million)
• Table 23.122 Cell and Gene Therapy Supply Chain Software Market in China: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
• Table 23.123 Cell and Gene Therapy Supply Chain Software Market in Japan: Historical Trends (2018-2023) (USD Million)
• Table 23.124 Cell and Gene Therapy Supply Chain Software Market in Japan: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
• Table 23.125 Cell and Gene Therapy Supply Chain Software Market in India: Historical Trends (2018-2023) (USD Million)
• Table 23.126 Cell and Gene Therapy Supply Chain Software Market in India: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
• Table 23.127 Cell and Gene Therapy Supply Chain Software Market in South Korea: Historical Trends (2018-2023) (USD Million)
• Table 23.128 Cell and Gene Therapy Supply Chain Software Market in South Korea: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
• Table 23.129 Cell and Gene Therapy Supply Chain Software Market in Rest of Asia-Pacific: Historical Trends (2018-2023) (USD Million)
• Table 23.130 Cell and Gene Therapy Supply Chain Software Market in Rest of Asia-Pacific: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
• Table 23.131 Cell and Gene Therapy Supply Chain Software Market in Rest of the World: Historical Trends (2018-2023) (USD Million)
• Table 23.132 Cell and Gene Therapy Supply Chain Software Market in Rest of the World: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
• Table 23.133 Cell and Gene Therapy Supply Chain Software Market in New Zealand: Historical Trends (2018-2023) (USD Million)
• Table 23.134 Cell and Gene Therapy Supply Chain Software Market in New Zealand: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
• Table 23.135 Cell and Gene Therapy Supply Chain Software Market in Brazil: Historical Trends (2018-2023) (USD Million)
• Table 23.136 Cell and Gene Therapy Supply Chain Software Market in Brazil: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
• Table 23.137 Cell and Gene Therapy Supply Chain Software Market in Israel: Historical Trends (2018-2023) (USD Million)
• Table 23.138 Cell and Gene Therapy Supply Chain Software Market in Israel: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)
• Table 23.139 Cell and Gene Therapy Supply Chain Software Market in Other Countries: Historical Trends (2018-2023) (USD Million)
• Table 23.140 Cell and Gene Therapy Supply Chain Software Market in Other Countries: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Million)

List of Figures

• Figure 2.1 Research Methodology: Project Methodology
• Figure 2.2 Research Methodology: Forecast Methodology
• Figure 2.3 Research Methodology: Robust Quality Control
• Figure 2.4 Research Methodology: Key Market Segmentations
• Figure 3.1 Lessons Learnt from Past Recessions
• Figure 4.1 Executive Summary: Cell and Gene Therapy Supply Chain Software Market Landscape
• Figure 4.2 Executive Summary: Funding and Investment Analysis
• Figure 4.3 Executive Summary: Partnerships and Collaborations
• Figure 4.4 Executive Summary: Market Forecast and Opportunity Analysis
• Figure 5.1 Classification of Advanced Therapy Medicinal Products
• Figure 5.2 Difference between Cell / Advanced Therapies and Other Biotechnology Products
• Figure 5.3 Components in the Cell and Gene Therapy Supply Chain
• Figure 5.4 Software Solutions for Cell and Gene Therapy Supply Chain Management
• Figure 5.5 Key Challenges in Cell and Gene Therapy Supply Chain
• Figure 6.1 Cell and Gene Therapy Supply Chain Software: Distribution by Type of Software
• Figure 6.2 Cell and Gene Therapy Supply Chain Software: Distribution by Key Features
• Figure 6.3 Cell and Gene Therapy Supply Chain Software: Distribution by Application Area
• Figure 6.4 Cell and Gene Therapy Supply Chain Software: Distribution by Mode of Deployment
• Figure 6.5 Cell and Gene Therapy Supply Chain Software: Distribution by Type of Software and Mode of Deployment
• Figure 6.6 Cell and Gene Therapy Supply Chain Software: Distribution by Scale of Operation
• Figure 6.7 Cell and Gene Therapy Supply Chain Software: Distribution by Type of Software and Scale of Operation
• Figure 6.8 Cell and Gene Therapy Supply Chain Software: Distribution by Regulatory Guidelines Followed
• Figure 6.9 Cell and Advanced Therapies Supply Chain Management Software: Distribution by Type of End-User
• Figure 6.10 Cell and Gene Therapy Supply Chain Software: Distribution by Type of Software and Type of End-User
• Figure 6.11 Cell and Gene Therapy Supply Chain Software Developers: Distribution by Year of Establishment
• Figure 6.12 Cell and Gene Therapy Supply Chain Software Developers: Distribution by Company Size
• Figure 6.13 Cell and Gene Therapy Supply Chain Software Developers: Distribution by Year of Establishment and Company Size
• Figure 6.14 Cell and Gene Therapy Supply Chain Software Developers: Distribution by Location of Headquarters (Region)
• Figure 6.15 Cell and Gene Therapy Supply Chain Software Developers: Distribution by Location of Headquarters (Country)
• Figure 6.16 Cell and Gene Therapy Supply Chain Software Developers: Distribution by Number of Software Solutions Offered
• Figure 6.17 Most Active Players: Distribution by Number of Software Solutions Offered
• Figure 7.1 Company Competitiveness Analysis: COP Developers
• Figure 7.2 Company Competitiveness Analysis: EMS Developers
• Figure 7.3 Company Competitiveness Analysis: IMS Developers
• Figure 7.4 Company Competitiveness Analysis: LIMS Developers
• Figure 7.5 Company Competitiveness Analysis: LMS Developers
• Figure 7.6 Company Competitiveness Analysis: PMS Developers
• Figure 7.7 Company Competitiveness Analysis: QMS Developers
• Figure 7.8 Company Competitiveness Analysis: TTS Developers
• Figure 8.1 Azenta Life Sciences: Annual Revenues, FY 2020-FY 2023 (USD Million)
• Figure 8.2 NMDP BioTherapies: Annual Revenues, FY 2019-FY 2022 (USD Million)
• Figure 8.3 BioLife Solutions: Annual Revenues, FY 2020-FY 2023 (USD Million)
• Figure 8.4 CareDx: Annual Revenues, FY 2018-FY 2021 (USD Million)
• Figure 8.5 Cryoport: Annual Revenues, FY 2019-9M FY 2023 (USD Million)
• Figure 8.6 Lonza: Annual Revenues, FY 2019-FY 2023 (CHF Million)
• Figure 8.7 Veeva Systems: Annual Revenues, FY 2020 - FY 2023 (USD Million)
• Figure 9.1 Funding and Investment Analysis: Cumulative Year-wise Trend, 2014-2023
• Figure 9.2 Funding and Investment Analysis: Distribution by Amount Invested, 2014-2023 (USD Million)
• Figure 9.3 Funding and Investment Analysis: Distribution by Type of Funding
• Figure 9.4 Funding and Investment Analysis: Distribution by Type of Funding and Amount Invested (USD Million)
• Figure 9.5 Funding and Investment Analysis: Distribution of Amount Invested by Year and Type of Funding, 2014-2023
• Figure 9.6 Funding and Investment Analysis: Geographical Distribution of Funding Instances and Amount Invested
• Figure 9.7 Funding and Investment Analysis: Geographical Distribution of Funding Instances (Country)
• Figure 9.8 Most Active Players: Distribution by Number of Funding Instances
• Figure 9.9 Most Active Players: Distribution by Amount Raised (USD Million)
• Figure 9.10 Key Investors: Distribution by Number of Funding Instances
• Figure 9.11 Funding and Investment Analysis: Distribution by Type of Investor
• Figure 10.1 Partnerships and Collaborations: Cumulative Year-wise Trend of Partnerships, 2019-2024
• Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
• Figure 10.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
• Figure 10.4 Partnerships and Collaborations: Distribution by Type of Partnership and Company Size
• Figure 10.5 Partnerships and Collaborations: Distribution by Type of Software Involved
• Figure 10.6 Partnerships and Collaborations: Distribution by Type of Partner
• Figure 10.7 Most Active Players: Distribution by Number of Partnerships
• Figure 10.8 Partnerships and Collaborations: Local and International Agreements
• Figure 10.9 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
• Figure 11.1 Platform Utilization Agreements: Cumulative Year-wise Trend of Agreements, 2019-2024
• Figure 11.2 Platform Utilization Agreements: Distribution by Type of Partner
• Figure 11.3 Platform Utilization Agreements: Distribution by Type of Software Involved
• Figure 11.4 Platform Utilization Agreements: Distribution by Type of Partner and Type of Software Involved
• Figure 11.5 Platform Utilization Agreements: Distribution of Partners by Geography
• Figure 11.6 Most active Players: Distribution by Number of Platform Utilization Agreements
• Figure 12.1 Cell and Gene Therapy Supply Chain: Stakeholder Needs
• Figure 12.2 Relative Importance of Stakeholders Needs
• Figure 13.1 Cell and Gene Therapy Supply Chain Software: Market Drivers
• Figure 13.2 Cell and Gene Therapy Supply Chain Software: Market Restraints
• Figure 13.3 Cell and Gene Therapy Supply Chain Software: Market Opportunities
• Figure 13.4 Cell and Gene Therapy Supply Chain Software: Market Challenges
• Figure 14.1 Global Cell and Gene Therapy Supply Chain Software Market, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
• Figure 14.2 Global Cell and Gene Therapy Supply Chain Software Market, Forecasted Estimates (2024-2035): Conservative Scenario (USD Million)
• Figure 14.3 Global Cell and Gene Therapy Supply Chain Software Market, Forecasted Estimates (2024-2035): Optimistic Scenario (USD Million)
• Figure 15.1 Cell and Gene Therapy Supply Chain Software Market: Distribution by Process Component, 2018, 2024 and 2035 (USD Million)
• Figure 15.2 Cell and Gene Therapy Supply Chain Software Market for Sample Collection and Processing Component, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
• Figure 15.3 Cell and Gene Therapy Supply Chain Software Market for Manufacturing Component, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
• Figure 15.4 Cell and Gene Therapy Supply Chain Software Market for Logistics Component, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
• Figure 15.5 Cell and Gene Therapy Supply Chain Software Market for Patient Identification and Treatment Follow-Up Component, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
• Figure 16.1 Cell and Gene Therapy Supply Chain Software Market: Distribution by Type of Software Solution, 2018, 2024 and 2035 (USD Million)
• Figure 16.2 Cell and Gene Therapy Supply Chain Software Market for EMS, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
• Figure 16.3 Cell and Gene Therapy Supply Chain Software Market for LIMS, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
• Figure 16.4 Cell and Gene Therapy Supply Chain Software Market for IMS, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
• Figure 16.5 Cell and Gene Therapy Supply Chain Software Market for COP, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
• Figure 16.6 Cell and Gene Therapy Supply Chain Software Market for QMS, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
• Figure 16.7 Cell and Gene Therapy Supply Chain Software Market for LMS, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
• Figure 16.8 Cell and Gene Therapy Supply Chain Software Market for PMS, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
• Figure 17.1 Cell and Gene Therapy Supply Chain Software Market: Distribution by Mode of Deployment, 2018, 2024 and 2035 (USD Million)
• Figure 17.2 Cell and Gene Therapy Supply Chain Software Market for On-premise Deployment, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
• Figure 17.3 Cell and Gene Therapy Supply Chain Software Market for Cloud-based Deployment, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
• Figure 18.1 Cell and Gene Therapy Supply Chain Software Market: Distribution by Scale of Operation, 2018, 2024 and 2035 (USD Million)
• Figure 18.2 Cell and Gene Therapy Supply Chain Software Market for Clinical Scale, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
• Figure 18.3 Cell and Gene Therapy Supply Chain Management Software Market for Commercial Scale, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
• Figure 19.1 Cell and Gene Therapy Supply Chain Software Market: Distribution by Type of End-User, 2018, 2024 and 2035 (USD Million)
• Figure 19.2 Cell and Gene Therapy Supply Chain Software Market for Pharmaceutical Companies, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
• Figure 19.3 Cell and Gene Therapy Supply Chain Software Market for Cell Therapy Labs, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
• Figure 19.4 Cell and Gene Therapy Supply Chain Software Market for Hospitals / Medical Centers, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
• Figure 19.5 Cell and Gene Therapy Supply Chain Software Market for Research Institutes / Biobanks, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
• Figure 20.1 Cell and Gene Therapy Supply Chain Software Market: Distribution by Key Geographical Regions, 2018, 2024 and 2035 (USD Million)
• Figure 20.2 Cell and Gene Therapy Supply Chain Software Market in North America, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
• Figure 20.3 Cell and Gene Therapy Supply Chain Software Market in the US, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
• Figure 20.4 Cell and Gene Therapy Supply Chain Software Market in Canada, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
• Figure 20.5 Cell and Gene Therapy Supply Chain Software Market in Europe, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
• Figure 20.6 Cell and Gene Therapy Supply Chain Management Software Market in the UK, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
• Figure 20.7 Cell and Gene Therapy Supply Chain Management Software Market in Germany, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
• Figure 20.8 Cell and Gene Therapy Supply Chain Software Market in France, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
• Figure 20.9 Cell and Gene Therapy Supply Chain Software Market in Italy, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
• Figure 20.10 Cell and Gene Therapy Supply Chain Software Market in Switzerland, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
• Figure 20.11 Cell and Gene Therapy Supply Chain Software Market in Rest of Europe, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
• Figure 20.12 Cell and Gene Therapy Supply Chain Software Market in Asia-Pacific, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
• Figure 20.13 Cell and Gene Therapy Supply Chain Software Market in Australia, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
• Figure 20.14 Cell and Gene Therapy Supply Chain Software Market in China, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
• Figure 20.15 Cell and Gene Therapy Supply Chain Software Market in Japan, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
• Figure 20.16 Cell and Gene Therapy Supply Chain Software Market in India, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
• Figure 20.17 Cell and Gene Therapy Supply Chain Software Market in South Korea, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
• Figure 20.18 Cell and Gene Therapy Supply Chain Software Market in Rest of Asia-Pacific, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
• Figure 20.19 Cell and Gene Therapy Supply Chain Software Market in Rest of the World, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
• Figure 20.20 Cell and Gene Therapy Supply Chain Software Market in New Zealand, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
• Figure 20.21 Cell and Gene Therapy Supply Chain Software Market in Brazil, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
• Figure 20.22 Cell and Gene Therapy Supply Chain Software Market in Israel, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
• Figure 20.23 Cell and Gene Therapy Supply Chain Software Market in Other Countries, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD million)
• Figure 21.1 Conclusion: Cell and Gene Therapy Supply Chain Software Market Landscape
• Figure 21.2 Conclusion: Funding and Investment Analysis
• Figure 21.3 Conclusion: Partnerships and Collaborations
• Figure 21.4 Conclusion: Market Forecast and Opportunity Analysis

The cell and gene therapy supply chain software market is valued at USD 274 billion in 2024 growing at a CAGR of 15.2% during the forecast period 2024-2035.

Pioneering cell and gene therapies have catalyzed a paradigm shift in healthcare delivery, revolutionizing the development, production, and consumption of cutting-edge medicine. These groundbreaking therapeutics have empowered healthcare professionals to combat rare clinical conditions that once seemed insurmountable. Over the past few decades, more than 30 such transformative modalities have garnered regulatory approval, with recent triumphs including ELEVIDYS(R) (2023), Adstiladrin(R) (2022), Breyanzi(R) (2022), CARVYKTI(R) (2022), Abecma(R) (2021), Allocord(TM) (2019), LUXTURNA(TM) (2017), and Yescarta(R) (2017). Moreover, a report by Novotech heralded the anticipated approval of more than 12 novel cell and gene therapies by the end of 2023, underscoring lucrative prospects for stakeholders in this burgeoning domain. Notably, post-2018, over 40% of clinical trials addressing rare diseases involved the evaluation of innovative cell and gene therapy products. Based on the current pipeline and historical clinical success rates, projections indicate that the United States Food and Drug Administration could approve 10-20 advanced therapies annually until 2025. Consequently, the demand for innovative software solutions to streamline supply chain management is poised to surge, presenting growth opportunities for cell and gene therapy software providers.

Importantly, the commercial triumph of cell and gene therapy products hinges not only on their therapeutic efficacy but also on developers' ability to seamlessly navigate complex supply chain intricacies. The cell and gene therapy supply chain is inherently more intricate than conventional pharmaceutical supply chains due to the temperature sensitivity and uniqueness of these products. Consequently, therapy developers must grapple with an array of risks, including operational inefficiencies, capacity scheduling challenges, process delays leading to capital losses, and delivery/tracking-related issues. This intricate landscape has fueled the need for tailored software solutions that can seamlessly integrate with existing processes, empowering drug developers to oversee and manage every aspect of the cell and gene therapy supply chain at each juncture. Over time, numerous innovative software solutions have emerged, offering supply chain orchestration and needle-to-needle traceability capabilities. The market has witnessed a surge in partnerships aimed at advancing these software solutions. Furthermore, driven by the growing demand for cost-effective personalized medicinal products and the cost-saving potential of implementing such software solutions, the cell and gene therapy supply chain software market is poised for substantial growth.

Key Market Segments

Process Component

• Sample Collection and Processing Component
• Manufacturing Component
• Logistics Component
• Patient Identification and Treatment Follow-up Component

Type of Software

• Enterprise Manufacturing System (EMS)
• Laboratory Information Management System (LIMS)
• Inventory Management System (IMS)
• Cell Orchestration Platform (COP)
• Quality Management System (QMS)
• Logistics Management System (LMS)
• Patient Management System (PMS)

Mode of Deployment

• On-premises Deployment
• Cloud-based Deployment

Type of End-User

• Pharmaceutical Companies
• Cell Therapy Labs
• Hospitals / Medical Centers
• Research Institutes / Biobanks

Type of End-User

• Clinical Scale
• Commercial Scale

Geographical Regions

• North America
• Europe
• Asia-Pacific
• Rest of the World

Research Coverage:

• The report studies the cell and gene therapy supply chain software market based on process component, type of software, mode of deployment, type of end-user, scale of operation and key geographical regions.
• The report assesses the potential advantages and obstacles within the market for those involved and offers information on the competitive environment for top players in the market.
• The report forecasts the revenue of market segments with respect to four major regions
• The report begins with a general overview of the cell and gene therapy supply chain, highlighting different types of software solutions, their key features, and applications. It also covers the advantages of supply chain software in this industry, challenges with conventional supply chains, and opportunities and future perspectives associated with supply chain management software.
• It provides a detailed overview of the current market landscape for cell and gene therapy supply chain software solutions, based on parameters such as software type (cell orchestration platform, enterprise manufacturing system, inventory management system, laboratory information management system, logistics management system, patient management system, quality management system, and tracking and tracing system), key features (compatibility/integration, traceability, data analytics/visualization, scalability, user-friendliness, chain of identity/custody), application area, mode of deployment, scale of operation, regulatory guidelines followed, and end-user type. Additionally, it lists developers offering these solutions, analyzing them based on establishment year, company size, headquarters location, and active players.
• The report offers an insightful competitiveness analysis of companies in this market, based on developer strength (experience, company size) and product portfolio strength (partnerships, application areas, features, end-users, deployment mode, operation scale, regulatory guidelines).
• It includes elaborate profiles of key software providers, featuring company overviews, software portfolios, financial information, recent developments, and future outlooks.
• The report provides an in-depth analysis of funding and investments in this domain since 2014, including seed funding, venture capital, debt financing, grants/awards, IPO proceeds, and subsequent offerings received by companies operating in this market.
• It presents a detailed analysis of partnerships, including acquisitions, platform utilization agreements, service alliances, platform integration agreements, product development agreements, service agreements, and others, inked between companies in this market since 2019.
• The report offers an in-depth analysis of platform utilization agreements signed since 2019, providing information on different software types utilized by end-users in the cell and gene therapy supply chain.
• It includes a qualitative assessment of current and long-term needs of different stakeholders (patients, healthcare providers, collection centers, manufacturers, logistics service providers, regulators/payers) involved in the cell and gene therapy supply chain, highlighting the diverse needs and their impact on the supply chain and industry preparedness.
• The report provides an in-depth analysis of factors impacting the growth of this market, including key drivers, potential restraints, emerging opportunities, and existing challenges.
• It offers a detailed estimate of the current market size and future growth potential of the cell and gene therapy supply chain software market until 2035, based on likely adoption trends and reliable secondary and primary validations. The report features three forecast scenarios (conservative, base, optimistic) to account for future uncertainties.
• The report includes detailed projections of the current and future market opportunity across various process components (sample collection/processing, manufacturing, logistics, patient identification/treatment follow-up), software types, deployment modes, operation scales, end-user types, and key geographical regions.

Key Benefits of Buying this Report

• The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
• Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
• The report provides stakeholders with a pulse on the cell and gene therapy supply chain software market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.

Key Market Companies

• Azenta Life Sciences
• Biocair
• BioLife Solutions
• CareDx
• Cryoport
• Lonza
• NMDP BioTherapies
• TraceLink
• TrakCel
• Veeva Systems
• Emerson
• LabVantage Solutions
• Marken
• MasterControl
• QuickSTAT
• Siemens
• Stafa Cellular Therapy
• Steiner
• STEMSOFT Software

TECHNIDATA

• Thermo Fisher Scientific

TABLE OF CONTENTS

1. PREFACE

• 1.1. Introduction
• 1.2. Market Share Insights
• 1.3. Key Market Insights
• 1.4. Report Coverage
• 1.5. Key Questions Answered
• 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

• 2.1. Chapter Overview
• 2.2. Research Assumptions
• 2.3. Project Methodology
• 2.4. Forecast Methodology
• 2.5. Robust Quality Control
• 2.6. Key Market Segmentations
• 2.7. Key Considerations
  • 2.7.1. Demographics
  • 2.7.2. Economic Factors
  • 2.7.3. Government Regulations
  • 2.7.4. Supply Chain
  • 2.7.5. COVID Impact
  • 2.7.6. Market Access
  • 2.7.7. Healthcare Policies
  • 2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

• 3.1. Chapter Overview
• 3.2. Market Dynamics
  • 3.2.1. Time Period
    • 3.2.1.1. Historical Trends
    • 3.2.1.2. Current and Future Estimates
  • 3.2.2. Currency Coverage and Foreign Exchange Rate
    • 3.2.2.1. Major Currencies Affecting the Market
    • 3.2.2.2. Factors Affecting Currency Fluctuations and Foreign Exchange Rates
    • 3.2.2.3. Impact of Foreign Exchange Rate Volatility on the Market
    • 3.2.2.4. Strategies for Mitigating Foreign Exchange Risks
  • 3.2.3. Trade Policies
    • 3.2.3.1. Impact of Trade Barriers on the Market
    • 3.2.3.2. Strategies for Mitigating the Risks associated with Trade Barriers
  • 3.2.4. Recession
    • 3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
    • 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
  • 3.2.5. Inflation
    • 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
    • 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

• 5.1. Chapter Overview
• 5.2. Overview of Cell Therapies
• 5.3. Advanced Therapy Medicinal Products (ATMPs)
  • 5.3.1. Difference between Cell / Advanced Therapies and Other Biotechnology Products
• 5.4. Overview of Cell and Gene Therapy Supply Chain
  • 5.4.1. Software Solutions for Cell and Gene Therapy Supply Chain
    • 5.4.1.1. Enterprise Manufacturing System (EMS)
    • 5.4.1.2. Laboratory Information Management System (LIMS)
    • 5.4.1.3. Inventory Management System (IMS)
    • 5.4.1.4. Quality Management System (QMS)
    • 5.4.1.5. Logistics Management System (LMS)
    • 5.4.1.6. Patient Management System (PMS)
    • 5.4.1.7. Cell Orchestration Platform (COP)
  • 5.4.2. Challenges in Cell and Advanced Therapy Supply Chain
• 5.5. Recent Developments and Future Outlook

6. MARKET LANDSCAPE

• 6.1. Chapter Overview
• 6.2. Cell and Gene Therapy Supply Chain Software: Overall Market Landscape
  • 6.2.1. Analysis by Type of Software
  • 6.2.2. Analysis by Key Features
  • 6.2.3. Analysis by Application Area
  • 6.2.4. Analysis by Mode of Deployment
  • 6.2.5. Analysis by Type of Software and Mode of Deployment
  • 6.2.6. Analysis by Scale of Operation
  • 6.2.7. Analysis by Type of Software and Scale of Operation
  • 6.2.8. Analysis by Regulatory Guidelines Followed
  • 6.2.9. Analysis by Type of End-User
  • 6.2.10. Analysis by Type of Software and End-User
• 6.3. Cell and Gene Therapy Supply Chain Software: Developer Landscape
  • 6.3.1. Analysis by Year of Establishment
  • 6.3.2. Analysis by Company Size
  • 6.3.3. Analysis by Year of Establishment and Company Size
  • 6.3.4. Analysis by Location of Headquarters
  • 6.3.5. Analysis by Number of Software Solutions Offered
  • 6.3.6. Most Active Players: Analysis by Number of Software Solutions Offered

7. COMPANY COMPETITIVENESS ANALYSIS

• 7.1. Chapter Overview
• 7.2. Assumptions and Key Parameters
• 7.3. Methodology
• 7.4. Company Competitiveness Analysis: Cell and Gene Therapy Supply Chain Software Providers
  • 7.4.1 COP Developers
  • 7.4.2. EMS Developers
  • 7.4.3. IMS Developers
  • 7.4.4. LIMS Developers
  • 7.4.5. LMS Developers
  • 7.4.6. PMS Developers
  • 7.4.7. QMS Developers
  • 7.4.8. TTS Developers

8. COMPANY PROFILES

• 8.1. Chapter Overview
• 8.2. Leading Players in Cell and Gene Therapy Supply Chain Software Market
  • 8.2.1. Azenta Life Sciences
    • 8.2.1.1. Company Overview
    • 8.2.1.2. Supply Chain Management Solutions Portfolio
    • 8.2.1.3. Financial Information
    • 8.2.1.4. Recent Developments and Future Outlook
  • 8.2.2. NMDP BioTherapies
    • 8.2.2.1. Company Overview
    • 8.2.2.2. Supply Chain Management Solutions Portfolio
    • 8.2.2.3. Financial Information
    • 8.2.2.4. Recent Developments and Future Outlook
  • 8.2.3. Biocair
    • 8.2.3.1. Company Overview
    • 8.2.3.2. Supply Chain Management Solutions Portfolio
    • 8.2.3.3. Recent Developments and Future Outlook
  • 8.2.4. BioLife Solutions
    • 8.2.4.1. Company Overview
    • 8.2.4.2. Supply Chain Management Solutions Portfolio
    • 8.2.4.3. Financial Information
    • 8.2.4.4. Recent Developments and Future Outlook
  • 8.2.5. CareDx
    • 8.2.5.1. Company Overview
    • 8.2.5.2. Supply Chain Management Solutions Portfolio
    • 8.2.5.3. Financial Information
    • 8.2.5.4. Recent Developments and Future Outlook
  • 8.2.6. Cryoport
    • 8.2.6.1. Company Overview
    • 8.2.6.2. Supply Chain Management Solutions Portfolio
    • 8.2.6.3. Financial Information
    • 8.2.6.4. Recent Developments and Future Outlook
  • 8.2.7. Lonza
    • 8.2.7.1. Company Overview
    • 8.2.7.2. Supply Chain Management Solutions Portfolio
    • 8.2.7.3. Financial Information
    • 8.2.7.3. Recent Developments and Future Outlook
  • 8.2.8. TraceLink
    • 8.2.8.1. Company Overview
    • 8.2.8.2. Supply Chain Management Solutions Portfolio
    • 8.2.8.4. Recent Developments and Future Outlook
  • 8.2.9. TrakCel
    • 8.2.9.1. Company Overview
    • 8.2.9.2. Supply Chain Management Solutions Portfolio
    • 8.2.9.3. Recent Developments and Future Outlook
  • 8.2.10. Veeva Systems
    • 8.2.10.1. Company Overview
    • 8.2.10.2. Supply Chain Management Solutions Portfolio
    • 8.2.10.3. Financial Information
    • 8.2.10.4. Recent Developments and Future Outlook
• 8.3. Other Leading Players in Cell and Gene Therapy Supply Chain Software Market
  • 8.3.1. Emerson
    • 8.3.1.1. Company Overview
    • 8.3.1.2. Supply Chain Management Solutions Portfolio
  • 8.3.2. LabVantage Solutions
    • 8.3.2.1. Company Overview
    • 8.3.2.2. Supply Chain Management Solutions Portfolio
  • 8.3.3. Marken
    • 8.3.3.1. Company Overview
    • 8.3.3.2. Supply Chain Management Solutions Portfolio
  • 8.3.4. MasterControl
    • 8.3.4.1. Company Overview
    • 8.3.4.2. Supply Chain Management Solutions Portfolio
  • 8.3.5. QuickSTAT
    • 8.3.5.1. Company Overview
    • 8.3.5.2. Supply Chain Management Solutions Portfolio
  • 8.3.6. Siemens
    • 8.3.6.1. Company Overview
    • 8.3.6.2. Supply Chain Management Solutions Portfolio
  • 8.3.7. Stafa Cellular Therapy
    • 8.3.7.1. Company Overview
    • 8.3.7.2. Supply Chain Management Solutions Portfolio
  • 8.3.8. Steiner
    • 8.3.8.1. Company Overview
    • 8.3.8.2. Supply Chain Management Solutions Portfolio
  • 8.3.9. STEMSOFT Software
    • 8.3.9.1. Company Overview
    • 8.3.9.2. Supply Chain Management Solutions Portfolio
  • 8.3.10. TECHNIDATA
    • 8.3.10.1. Company Overview
    • 8.3.10.2. Supply Chain Management Solutions Portfolio
  • 8.3.11. Thermo Fisher Scientific
    • 8.3.11.1. Company Overview
    • 8.3.11.2. Supply Chain Management Solutions Portfolio

9. FUNDING AND INVESTMENT ANALYSIS

• 9.1. Chapter Overview
• 9.2. Funding Models
• 9.3. Cell and Gene Therapy Supply Chain Software: Funding and Investment Analysis
  • 9.3.1. Analysis by Year of Funding
  • 9.3.2. Analysis by Amount Invested
  • 9.3.3. Analysis by Type of Funding
  • 9.3.4. Analysis by Type of Funding and Amount Invested
  • 9.3.5. Analysis of Amount Invested by Year and Type of Funding
  • 9.3.6. Analysis by Geography
  • 9.3.7. Most Active Players: Analysis by Number of Instances
  • 9.3.8. Most Active Players: Analysis by Amount Raised
  • 9.3.9. Key Investors: Analysis by Number of Funding Instances
  • 9.3.10. Analysis by Type of Investor
• 9.5. Concluding Remarks

10. PARTNERSHIPS AND COLLABORATIONS

• 10.1. Chapter Overview
• 10.2. Partnership Models
• 10.3. Cell and Gene Therapy Supply Chain Software: Partnerships and Collaborations
  • 10.3.1. Analysis by Year of Partnership
  • 10.3.2. Analysis by Type of Partnership
  • 10.3.3. Analysis by Year and Type of Partnership
  • 10.3.4. Analysis by Type of Partnership and Company Size
  • 10.3.5. Analysis by Type of Partner
  • 10.3.6. Analysis by Type of Software Involved
  • 10.3.7. Most Active Players: Analysis by Number of Partnerships
  • 10.3.8. Analysis by Geography
    • 10.3.8.1. Local and International Agreements
    • 10.3.8.2. Intracontinental and Intercontinental Agreements

11. PLATFORM UTILIZATION AGREEMENTS IN SUPPLY CHAIN SOFTWARE SOLUTIONS MARKET

• 11.1. Chapter Overview
• 11.2. Platform Utilization Agreements in Supply Chain Software Solutions Market: List of Agreements
  • 11.2.1. Analysis by Year of Agreement
  • 11.2.2. Analysis by Type of Partner
  • 11.2.3. Analysis by Type of Software Involved
  • 11.2.4. Analysis by Type of Partner and Type of Software Involved
  • 11.2.5. Analysis of Partners by Geography
  • 11.2.5. Most Active Players: Analysis by Number of Platform Utilization Agreements

12. STAKEHOLDER NEEDS ANALYSIS

• 12.1. Chapter Overview
• 12.2. Cell and Gene Therapy Supply Chain: Needs of Different Stakeholders
  • 12.2.1. Comparison of Stakeholder Needs
  • 12.2.2. Conclusion

13. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

• 13.1. Chapter Overview
• 13.2. Market Drivers
• 13.3. Market Restraints
• 13.4. Market Opportunities
• 13.5. Market Challenges
• 13.6. Conclusion

14. GLOBAL CELL AND GENE THERAPY SUPPLY CHAIN SOFTWARE MARKET

• 14.1. Chapter Overview
• 14.2. Assumptions and Methodology
• 14.3. Global Cell and Gene Therapy Supply Chain Software Market, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
  • 14.3.1. Scenario Analysis
    • 14.3.1.1. Conservative Scenario
    • 14.3.1.2. Optimistic Scenario
• 14.4. Key Market Segmentations
• 14.5. Dynamic Dashboard

15. CELL AND GENE THERAPY SUPPLY CHAIN SOFTWARE MARKET, BY PROCESS COMPONENT

• 15.1. Chapter Overview
• 15.2. Key Assumptions and Methodology
• 15.3. Cell and Gene Therapy Supply Chain Software Market: Distribution by Process Component, 2018, 2024 and 2035
  • 15.3.1. Cell and Gene Therapy Supply Chain Software Market for Sample Collection and Processing Component: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
  • 15.3.2. Cell and Gene Therapy Supply Chain Software Market for Manufacturing Component: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
  • 15.3.3. Cell and Gene Therapy Supply Chain Software Market for Logistics Component: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
  • 15.3.4. Cell and Gene Therapy Supply Chain Software Market for Patient Identification and Treatment Follow-Up Component: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
• 15.4. Data Triangulation and Validation

16. CELL AND GENE THERAPY SUPPLY CHAIN SOFTWARE MARKET, BY TYPE OF SOFTWARE

• 16.1. Chapter Overview
• 16.2. Key Assumptions and Methodology
• 16.3. Cell and Gene Therapy Supply Chain Software Market: Distribution by Type of Software, 2018, 2024 and 2035
  • 16.3.1. Cell and Gene Therapy Supply Chain Software Market for EMS: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
  • 16.3.2. Cell and Gene Therapy Supply Chain Software Market for LIMS: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
  • 16.3.3. Cell and Gene Therapy Supply Chain Software Market for IMS: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
  • 16.3.4. Cell and Gene Therapy Supply Chain Software Market for COP: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
  • 16.3.5. Cell and Gene Therapy Supply Chain Software Market for QMS: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
  • 16.3.6. Cell and Gene Therapy Supply Chain Software Market for LMS: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
  • 16.3.7. Cell and Gene Therapy Supply Chain Software Market for PMS: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
• 16.4. Data Triangulation and Validation

17. CELL AND GENE THERAPY SUPPLY CHAIN SOFTWARE MARKET, BY MODE OF DEPLOYMENT

• 17.1. Chapter Overview
• 17.2. Key Assumptions and Methodology
• 17.3. Cell and Gene Therapy Supply Chain Software Market: Distribution by Mode of Deployment, 2018, 2024 and 2035
  • 17.3.1. Cell and Gene Therapy Supply Chain Software Market for On-premise Deployment: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
  • 17.3.2. Cell and Gene Therapy Supply Chain Software Market for Cloud-based Deployment: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
• 17.4. Data Triangulation and Validation

18. CELL AND GENE THERAPY SUPPLY CHAIN SOFTWARE MARKET, BY SCALE OF OPERATION

• 18.1. Chapter Overview
• 18.2. Key Assumptions and Methodology
• 18.3. Cell and Gene Therapy Supply Chain Software Market: Distribution by Scale of Operation, 2018, 2024 and 2035
  • 18.3.1. Cell and Gene Therapy Supply Chain Software Market for Clinical Scale: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
  • 18.3.2. Cell and Gene Therapy Supply Chain Software Market for Commercial Scale: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
• 18.4. Data Triangulation and Validation

19. CELL AND GENE THERAPY SUPPLY CHAIN SOFTWARE MARKET, BY TYPE OF END-USER

• 19.1. Chapter Overview
• 19.2. Key Assumptions and Methodology
• 19.3. Cell and Gene Therapy Supply Chain Software Market: Distribution by Type of End-User, 2018, 2024 and 2035
  • 19.3.1. Cell and Gene Therapy Supply Chain Software Market for Pharmaceutical Companies: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
  • 19.3.2. Cell and Gene Therapy Supply Chain Software Market for Cell Therapy Labs: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
  • 19.3.3. Cell and Gene Therapy Supply Chain Software Market for Hospitals / Medical Centers: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
  • 19.3.4. Cell and Gene Therapy Supply Chain Software Market for Research Institutes / Biobanks: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
• 19.4. Data Triangulation and Validation

20. CELL AND GENE THERAPY SUPPLY CHAIN SOFTWARE MARKET, BY KEY GEOGRAPHICAL REGIONS

• 20.1. Chapter Overview
• 20.2. Key Assumptions and Methodology
• 20.3. Cell and Gene Therapy Supply Chain Software Market: Distribution by Key Geographical Regions, 2018, 2024 and 2035
  • 20.3.1. Cell and Gene Therapy Supply Chain Software Market in North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
    • 20.3.1.1. Cell and Gene Therapy Supply Chain Software Market in the US: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
    • 20.3.1.2. Cell and Gene Therapy Supply Chain Software Market in Canada: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
  • 20.3.2. Cell and Gene Therapy Supply Chain Software Market in Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
    • 20.3.2.1. Cell and Gene Therapy Supply Chain Software Market in the UK: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
    • 20.3.2.2. Cell and Gene Therapy Supply Chain Software Market in Germany: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
    • 20.3.2.3. Cell and Gene Therapy Supply Chain Software Market in France: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
    • 20.3.2.4. Cell and Gene Therapy Supply Chain Software Market in Italy: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
    • 20.3.2.5. Cell and Gene Therapy Supply Chain Software Market in Switzerland: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
    • 20.3.2.6. Cell and Gene Therapy Supply Chain Software Market in Rest of Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
  • 20.3.3. Cell and Gene Therapy Supply Chain Software Market in Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
    • 20.3.3.1. Cell and Gene Therapy Supply Chain Software Market in Australia: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
    • 20.3.3.2. Cell and Gene Therapy Supply Chain Software Market in China: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
    • 20.3.3.3. Cell and Gene Therapy Supply Chain Software Market in Japan: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
    • 20.3.3.4. Cell and Gene Therapy Supply Chain Software Market in India: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
    • 20.3.3.5. Cell and Gene Therapy Supply Chain Software Market in South Korea: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
    • 20.3.3.6. Cell and Gene Therapy Supply Chain Software Market in Rest of Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
  • 20.3.4. Cell and Gene Therapy Supply Chain Software Market in Rest of the World: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
    • 20.3.4.1. Cell and Gene Therapy Supply Chain Software Market in New Zealand: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
    • 20.3.4.2. Cell and Gene Therapy Supply Chain Software Market in Brazil: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
    • 20.3.4.3. Cell and Gene Therapy Supply Chain Software Market in Israel: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
    • 20.3.4.4. Cell and Gene Therapy Supply Chain Software Market in Other Countries: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
• 20.4. Data Triangulation and Validation

21. CONCLUSION

22. EXECUTIVE INSIGHTS

• 22.1. Chapter Overview
• 22.2. TrakCel
  • 22.2.1. Company Snapshot
  • 22.2.2. Interview Transcript: Martin Lamb, (Former Chief Business Officer)
• 22.3. Cell and Gene Therapy Catapult
  • 22.3.1. Company Snapshot
  • 22.3.2. Interview Transcript: Jacqueline Barry, Chief Clinical Officer
• 22.4. McKesson
  • 22.4.1. Company Snapshot
  • 22.4.2. Interview Transcript: Divya Iyer, Former Senior Director, Corporate Strategy and Business Development
• 22.5. Inlog
  • 22.5.1. Company Snapshot
  • 22.5.2. Interview Transcript: David Delay, International Sales and Transfusion Manager
• 22.6. Thermo Fisher Scientific
  • 22.6.1. Company Snapshot
  • 22.6.2. Interview Transcript: Bryan Poltilove, Former General Manager, Cell and Gene Therapy

23. APPENDIX 1: TABULATED DATA

24. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS